







| Inalyte | Value | Ref. Range | | Units Abn. Fl | ag Status | Lab |
|--------------------------------|---------------|--|----------------------|--|-----------|-----------------------------|
| HDL cholesterol | 47 | >39 | | mg/dL | final | SPARROW REGIONAL LABORATORY |
| holesterol | 163 | see below | | mg/dL | final | SPARROW REGIONAL LABORATORY |
| Age Ran | ge | | | | | |
| <19 110 19+ | - 170 <200 | | | | | |
| riglycerides | 137 | <150 | | mg/dL | final | SPARROW REGIONAL LABORATORY |
| holesterol/HDL ratio | 3.5 | male < 5.1 female | <4.5 | | final | SPARROW REGIONAL LABORATORY |
| .DL cholesterol, salculated | 89 | <130 | | mg/dL | final | SPARROW REGIONAL LABORATORY |
| Analyte | Value | Ref. Range | Units | Abn. Flag | Status | Lab |
| apolipoprotein B | 100 | <90 | mg/dL | high | final | SPARROW REGIONAL LABORATORY |
| | | Desirabl Borderli High Very Hig | le ine High gh | <pre>< 90 90 - 99 100 - 130 >130</pre> | | |







| | DL IOT WILLISK | L | Charles a | |
|---|--|--|--|---------------------------------|
| - Purpose: To dete VII risk assessme | ermine if the <u>numb</u> ent than traditional | er of apoB-contain | ing lipoproteins p cholesterol and ti | provides better riglycerides |
| without establishe | ed ASCVD & not o | n statins; 2) Secon | dary prevention | group: 40,430 |
| x age 63, 24% Design & Primar Cholesterol (HDL- | ry outcome: Meas -C), LDL-C, and TC | sures of ApoB, non G (mg/dL) and risk | -high-density lip of MI. | oprotein |
| , x age 63, 24% (Design & Primar cholesterol (HDL- | ry outcome: Meas | sures of ApoB, non G (mg/dL) and risk Baseline Measures | -high-density lip of MI. | oprotein |
| Primary Prevention | ry outcome: Meas -C), LDL-C, and TC LDL 142 | sures of ApoB, non G (mg/dL) and risk Baseline Measures NonHDL 168 | -high-density lip of MI. TG 127 | oprotein ApoB 105 |



#1: Apod S > LDL for Mirish

 Image: Constraints
 Image: Constraints

 Image: Constraints
 Image: Constraints
</tr

















So, lipoproteins (like their name implies) are macromolecules of

Apolipoproteins are lettered (A, B, C, D, E, H , e.g., ApoB, ApoA)

Note the CAPITALIZATION of the letters

Lipoproteins and Apolipoproteins

protein and lipids that facilitates transport













Slide 27

FG1 Ferenchick, Gary, 6/13/2022









Statin Intolerance























